Boehringer Ingelheim's Survodutide Achieves Up to 13.1% Weight Loss in New Phase III Trial, Alongside Significant Improvements in Glycemic Control in People With Obesity, Type 2 Diabetes
October 02, 2026
October 02, 2026
INGELHEIM AM RHEIN, Germany, Oct. 2 (TNSjou) -- Boehringer Ingelheim, a pharmaceutical company, issued the following news release:
* * *
Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
Ingelheim, Germany, Thu, 01/10/2026
* In the SYNCHRONIZE-2 trial, which met its co-primary endpoints, participants a . . .
* * *
Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
Ingelheim, Germany, Thu, 01/10/2026
* In the SYNCHRONIZE-2 trial, which met its co-primary endpoints, participants a . . .